Monograph Details
|
|
Neoplasms
> Topoisomerase inhibitors
|
|
VUMON |
| Manufacturer |
|
Bristol-Myers Squibb |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Topoisomerase inhibitor |
| Generic Name |
|
Teniposide 10mg/mL; soln for IV infusion after dilution; contains benzyl alcohol, Cremophor EL (polyoxyethylated castor oil), dehydrated alcohol. |
| Indications |
|
Refractory childhood acute lymphoblastic leukemia. |
| Adults and Children |
|
See literature. Give as slow IV infusion (at least 30–60 minutes). Patients failing induction therapy with a cytarabine-containing regimen: 165mg/m2 + cytarabine twice weekly for 8 to 9 doses. Refractory to vincristine/prednisone-containing regimen: 250mg/m2 + vincristine weekly for 4 to 8 weeks + oral prednisone for 28 days. |
| Precautions |
|
Severe myelosuppression. Monitor for hypersensitivity reactions following infusion; have epinephrine available. Risk of hypotension with rapid IV administration. Monitor and obtain CBCs with differential, hemoglobin, platelets, renal and hepatic functions before, during, and after therapy. Down syndrome (use reduced dose). Avoid extravasation. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended. |
| Interactions |
|
Potentiated by tolbutamide, sodium salicylate, and sulfamethizole. |
| Adverse Reactions |
|
Myelosuppression (leukopenia, neutropenia, thrombocytopenia, anemia), mucositis, GI upset, infection, alopecia, bleeding, rash, fever, hypotension, hypersensitivity reactions (may be fatal). |
| How Supplied |
|
Ampules (5mL)—1 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
